We previously reported that high AnxA6 and low RasGRF2 expression is associated with poorer distant relapse-free survival of basal-like breast cancer patients compared to patients with low AnxA6 and high GRF2 expressing basal-like breast cancer. Here, RASGRF2 is linked to breast carcinoma.